Advantages of Liquid Biopsy in Cancer that Causing Demand increased in the Global Liquid Biopsy Market

The global liquid biopsy market is anticipated to grow at a significant CAGR of 17.3% during the forecast period (2022-2028). The liquid biopsy diagnosis has been driven by several factors, and one of them is the advantages it offers over the other process. Liquid biopsy is a process that requires body liquid. There are several body fluids that contain genetic material derived from tumors such as urine, saliva, stool, blood, and cerebrospinal fluid (CSF). The main advantages of liquid biopsies are:

• Minimally invasive
• Low risk
• High throughput
• Rapid
• Real-time

These advantages help in Identifying targeted treatments and clinical trial eligibility for patients. It informs which tissue-based testing is not appropriate or is not available, liquid biopsy can offer a safe alternative test for determining targeted therapy or eligibility for inclusion in clinical trials.

Browse the full report description “Global Liquid Biopsy Market Size, Share & Trends Analysis Report, by Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, and Others), by Cancer Type (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, and Other Cancers), and by End-User (Hospitals and Laboratories, and Academic and Research Centres) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/liquid-biopsy-market

Moreover, it also helps in monitoring the treatment or disease with its minimally invasive, rapid, and economical test which provides real-time information about a tumor. With all these advantages this process has been projected to grow significantly during the forecast period. 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Biomarker Type
• By Cancer Type
• By End-User

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- including Bio-Rad Laboratories Inc., CellMax Life, Guardant Health Inc., MDxHealth SA, QIAGEN NV, and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

oDeviation from the pre-COVID-19 forecast

oMost affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Liquid BiopsyMarket Report Segment

By Biomarker Type

• Circulating Tumor Cells
• Circulating Tumor DNA (ctDNA)
• Others (Extracellular Vesicles)

By Cancer Type 

• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Other Cancers

By End-User

• Hospitals and Laboratories
• Academic and Research Centres

Global Liquid Biopsy Market Report Segment by Region

North America

• US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/industry-reports/liquid-biopsy-market